



Medicago Announces Additional Positive Results for its H5N1 Avian Influenza VLP vaccine

- Preclinical results demonstrate effectiveness of vaccine even at extremely low doses -

Quebec City, Quebec, November 20, 2007 — Medicago Inc. (TSX-V: MDG) today announced additional positive results from a preclinical study of its H5N1 Influenza Virus-Like Particles (“VLP”) vaccine. Medicago previously reported that its proprietary VLP vaccine stimulates a significant seroprotective immune response against the lethal Indonesia strain of the H5N1 Avian Influenza virus in mice who received doses as low as 1 microgram (ug). The Company has now generated additional data showing that a strong protective immune response is achieved against this virus at even lower doses of only 0.1 ug.

“These unprecedented data position Medicago at the forefront of influenza vaccine development,” said Andy Sheldon, President and CEO. “A typical dose for a pandemic flu vaccine is 15-30 ug. If we are able to reproduce these results in human clinical trials, our technology has the potential to significantly increase the world’s currently limited vaccine manufacturing capacity, allowing for the protection of a greater number of people in the event of a pandemic influenza outbreak.”

“This 0.1ug dose is amongst the lowest doses ever recorded,” said Dr. Louis Vezina, Medicago’s Chief Scientific Officer. “At this very low dose, Medicago’s VLP vaccine generated neutralizing antibody levels in mice three times higher than the minimal level required to obtain protection against an influenza infection. Based on these results, we will continue studies to determine the lowest effective dose”

About Medicago Inc.

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com

Forward Looking Statements

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

Contact Information

Medicago Inc.
Andy Sheldon
President and CEO
(418) 658-9393

The Equicom Group Inc.
Eric Bouchard
Investor Relations
(514) 844-7997
ebouchard@equicomgroup.com